Expres≰Mail Label No.: ED 9087333 Attorney Docket No.: 100869-1P US

Under the Paperwork Reduction Act of 1995, no

Approved for use through 03/31/2007. OMB 0651-0021
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE nd to a collection of information unless it displays a valid OMB control number.

Docket Number

LTRABE PETITION FOR REVIVAL OF AN INTERNATIONAL APPLICATION FOR PATENT DESIGNATING THE U.S. ABANDONED UNINTENTIONALLY UNDER 37 CFR 1.137(b)

(Optional) 100869-1P-US

First Named Inventor: Michael Barry Gravestock

International (PCT) Application No.: PCT/GB2004/001132

U.S. Application No.:

(if known)

Filed: March 20, 2003

Title: Antibacterial Oxazolidinones

Attention: PCT Legal Staff Mail Stop PCT

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

The above-identified application became abandoned as to the United States because the fees and documents required by 35 U.S.C. 371(c) were not filed prior to the expiration of the time set in 37 CFR 1.495(b) or (c) as applicable. The date of abandonment is the day after the date on which the 35 U.S.C. 371(c) requirements were due. See 37 CFR 1.495(h).

APPLICANT HEREBY PETITIONS FOR REVIVAL OF THIS APPLICATION

NOTE: A grantable petition requires the following items:

- (1) Petition fee
- (2) Proper reply
- (3) Terminal disclaimer with disclaimer fee which is required for all international applications having an international filing date before June 8, 1995; and
- Statement that the entire delay was unintentional

(4) Statement that the entire delay was drimtentional.
1. Petition fee Small entity - fee \$(37 CFR 1.17(m)). Applicant claims small entity status. See 37 CFR 1.27.
Other than small entity - fee \$ See 1 (37 CFR 1.17(m))
Proper-Perply
A. The proper reply (the missing 35 U.S.C. 371(c) requirement(s)) in the form of Form PTO-1390 (identify type of reply):
\overline{X} has been filed previously on See 2 in Addendum
is enclosed herewith.

[Page 1 of 2]

This collection of information is required by 37 CFR 1.137(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PTO/SB/64/PCT (12-04)
Approved for use through 03/31/2007. OMB 0651-0021
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

3. Terminal disclaimer with disclaimer fee	tor lune 9, 1005, no terminal disclaimer.
Since this international application has an international filing date on or af is required.	ter June 8, 1995, no terminal disclaimer
A terminal disclaimer (and disclaimer fee (37 CFR 1.20(d)) of \$ for other than a small entity) disclaiming the required period (see PTO/SB/63).	for a small entity or od of time is enclosed herewith
 Statement. The entire delay in filing the required reply from the due date for the filing of a grantable petition under 37 CFR 1.137(b) was unintentional. 	he required reply until the
WARNING: Information on this form may become public. Credit ca be included on this form. Provide credit card information and aut	rd information should not horization on PTO-2038.
	23 Sept 2005
gignature	Date
Heidi M. Berven	48,951
Typed or Printed Name	Registration Number, if applicable
AstraZeneca R&D Boston	781-839-4336
Address	Telephone Number
35 Gatehouse Drive Waltham MA 02451	
Address	
Enclosures: X Response Fee Payment Terminal Disclaimer Other (please identify): Copies of form associated info	1390 and rmation